Cambridge Cognition Holdings PLC on Tuesday said that it has won a £2 million contract for a cancer therapy trial, for which it will provide its proprietary cognitive assessments.

Cambridge Cognition is a Cambridgeshire, England-based company which develops and markets digital solutions to assess brain health.

The firm didn’t say with whom it had signed the deal, only that it would be working with a ‘major pharmaceutical company’.

Under the terms of the agreement, Cambridge Cognition will provide its proprietary cognitive assessments as an exploratory endpoint, with revenue expected over the next five years.

Its software products assess cognitive health in patients in order to improve clinical trial outcomes, identifying and stratifying patients early.

‘Advances in cancer treatment have led to increased consideration for limiting the side-effects that impact patients’ quality of life. Reducing cognitive impairment could have a major impact on patients’ lives,’ said Chief Executive Officer Matthew Stork.

‘We are pleased to be working with a major pharmaceutical company to support their development programme. With significant investment being made in cancer trials by the world’s leading pharmaceutical companies, we expect that this could become a considerable growth area for Cambridge Cognition in the future.’

Cambridge Cognition shares were trading 2.9% higher at 101.90 pence each in London on Tuesday morning.

Copyright 2023 Alliance News Ltd. All Rights Reserved.